Persistent lymphopenia after dimethyl fumarate and fingolimod treatment

被引：0
|
作者：
Hernandez, I. [1 ]
Mulero, P. [1 ]
Neri, M. J. [1 ]
Redondo, N. [1 ]
Abad, E. [2 ]
Tellez, N. [1 ]
机构：
[1] Hosp Clin Valladolid, Neurol, Valladolid, Spain
[2] Hosp Clin Valladolid, Pharm, Valladolid, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P775
引用
收藏
页码：644 / 645
页数：2
相关论文
共 50 条
  • [1] Lymphopenia with dimethyl fumarate and fingolimod in clinical practice
    Hersh, C. M.
    Cohn, S.
    Hara-Cleaver, C.
    Bermel, R. A.
    Fox, R. J.
    Cohen, J. A.
    Ontaneda, D.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 349 - 350
  • [2] Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, Maryam
    Barilla, David
    Lee, Chieh-Hsin
    Blevins, Gregg
    Giuliani, Fabrizio
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (02):
  • [3] Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation
    Caldito, Natalia Gonzalez
    O'Leary, Shirley
    Stuve, Olaf
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (08) : 1306 - 1308
  • [4] INCIDENCE OF PERSISTENT LYMPHOPENIA IN PEOPLE WITH MULTIPLE SCLEROSIS ON DIMETHYL FUMARATE
    Wood, Callum
    Pickersgill, Trevor
    Willis, Mark
    Robertson, Neil
    Tallantyre, Emma
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [5] Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate
    Wood, Callum H.
    Robertson, Neil P.
    Htet, Zin Min
    Tallantyre, Emma C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [6] Persistent lymphopenia after routine clinical use of dimethyl fumarate for relapsing remitting multiple sclerosis
    MacDougall, N. J.
    Gallagher, P.
    Murdoch, S.
    Murray, L.
    Webb, S.
    Overell, J. R.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 300 - 300
  • [7] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
  • [8] Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
    Vollmer, Brandi L.
    Nair, Kavita V.
    Sillau, Stefan
    Corboy, John R.
    Vollmer, Timothy
    Alvarez, Enrique
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (02): : 252 - 262
  • [9] Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
    Zhu, Chao
    Kalincik, Tomas
    Horakova, Dana
    Zhou, Zhen
    Buzzard, Katherine
    Skibina, Olga
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau, Sara
    Kuhle, Jens
    Patti, Francesco
    Grand'Maison, Francois
    Hodgkinson, Suzanne
    Grammond, Pierre
    Lechner-Scott, Jeannette
    Butler, Ernest
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Macdonell, Richard A. L.
    Weinstock-Guttman, Bianca
    Ozakbas, Serkan
    Slee, Mark
    Sa, Maria Jose
    Van Pesch, Vincent
    Barnett, Michael
    Van Wijmeersch, Bart
    Gerlach, Oliver
    Prevost, Julie
    Terzi, Murat
    Boz, Cavit
    Laureys, Guy
    Van Hijfte, Liesbeth
    Kermode, Allan G.
    Garber, Justin
    Yamout, Bassem
    Khoury, Samia J.
    Merlo, Daniel
    Monif, Mastura
    Jokubaitis, Vilija
    van der Walt, Anneke
    Butzkueven, Helmut
    MSBase Study Grp
    JAMA NEUROLOGY, 2023, 80 (07) : 739 - 748
  • [10] Persistent severe lymphopenia of at least one-year duration after dimethyl fumarate discontinuation: three case reports
    Caldito, N. Gonzalez
    O'Leary, S.
    Stuve, O.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 296 - 297
12345